Literature DB >> 2858014

Sulindac treatment for familial polyposis coli.

R A Gonzaga, F R Lima, S Carneiro, J Maciel, M Amarante Júnior.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2858014     DOI： 10.1016/s0140-6736(85)91286-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Effects of sulindac on sporadic colorectal adenomatous polyps.

Authors:  N Matsuhashi; A Nakajima; Y Fukushima; Y Yazaki; T Oka
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

Review 2.  Clinical pharmacokinetics of sulindac. A dynamic old drug.

Authors:  N M Davies; M S Watson
Journal:  Clin Pharmacokinet       Date:  1997-06       Impact factor: 6.447

Review 3.  Sulindac and polyp regression.

Authors:  F M Giardiello
Journal:  Cancer Metastasis Rev       Date:  1994-12       Impact factor: 9.264

Review 4.  Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer. At what cost?

Authors:  M A Trujillo; H S Garewal; R E Sampliner
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

5.  The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration.

Authors:  G Winde; H G Gumbinger; H Osswald; F Kemper; H Bünte
Journal:  Int J Colorectal Dis       Date:  1993-03       Impact factor: 2.571
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.